Minor neuropsychological deficits in patients with subjective cognitive decline.

Objective To determine the nature and extent of minor neuropsychological deficits in patients with subjective cognitive decline (SCD) and their association with CSF biomarkers of Alzheimer disease (AD). Method We analyzed data from n = 449 cognitively normal participants (n = 209 healthy controls, n = 240 patients with SCD) from an interim data release of the German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia Study (DELCODE). An extensive neuropsychological test battery was applied at baseline for which we established a latent, 5 cognitive domain factor structure comprising learning and memory, executive functions, language abilities, working memory, and visuospatial functions. We compared groups in terms of global and domain-specific performance and correlated performance with different CSF markers of AD pathology. Results We observed worse performance (Cohen d = ≈0.25–0.5, adjusted for age, sex differences with analysis of covariance) in global performance, memory, executive functions, and language abilities for the SCD group compared to healthy controls. In addition, worse performance in these domains was moderately (r = ≈0.3) associated with lower CSF β-amyloid42/40 and CSF β-amyloid42/phosphorylated tau181 in the whole sample and specifically in the SCD subgroup. Conclusions Within the spectrum of clinically unimpaired (i.e., before mild cognitive impairment) cognitive performance, SCD is associated with minor deficits in memory, executive function, and language abilities. The association of these subtle cognitive deficits with AD CSF biomarkers speaks to their validity and potential use for the early detection of underlying preclinical AD.

[1]  Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring announces new editor‐in‐chief for open access, peer reviewed journal , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[2]  P. Scheltens,et al.  High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline , 2019, Neuropsychologia.

[3]  F. Jessen,et al.  Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study , 2019, Alzheimer's Research & Therapy.

[4]  W. M. van der Flier,et al.  Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project , 2019, Neurobiology of Aging.

[5]  C. Jack,et al.  Neural correlates of domain-specific cognitive decline , 2019, Neurology.

[6]  W. M. van der Flier,et al.  Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples , 2019, Alzheimer's Research & Therapy.

[7]  John E. Harrison,et al.  FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry” , 2019, Alzheimer's & dementia.

[8]  W. M. van der Flier,et al.  Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia , 2018, Alzheimer's & Dementia.

[9]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[10]  S. Engelborghs,et al.  Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis , 2018, Journal of Alzheimer's disease : JAD.

[11]  F. Jessen,et al.  Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE) , 2018, Alzheimer's Research & Therapy.

[12]  W. M. van der Flier,et al.  Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. , 2017, Biological psychiatry. Cognitive neuroscience and neuroimaging.

[13]  A. Saykin,et al.  Incidence of cognitively defined late-onset Alzheimer's dementia subgroups from a prospective cohort study , 2017, Alzheimer's & Dementia.

[14]  W. Jagust,et al.  Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly , 2017, Neurology.

[15]  C. Smart,et al.  Subjective Cognitive Decline in Preclinical Alzheimer's Disease. , 2017, Annual review of clinical psychology.

[16]  Denis Guilloteau,et al.  Subjective cognitive decline in cognitively normal elders from the community or from a memory clinic: Differential affective and imaging correlates , 2017, Alzheimer's & Dementia.

[17]  Andrew J. Saykin,et al.  Implementation of subjective cognitive decline criteria in research studies , 2017, Alzheimer's & Dementia.

[18]  P. Snyder,et al.  Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis , 2016, Alzheimer's & dementia.

[19]  Pierrick Bourgeat,et al.  Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease , 2016, Alzheimer's & Dementia.

[20]  Philip S. Insel,et al.  Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis , 2016, Nature Communications.

[21]  J. Becker,et al.  Amyloid-β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. , 2015, Journal of Alzheimer's disease : JAD.

[22]  D. Harvey,et al.  Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease , 2015, Alzheimer's & Dementia.

[23]  C. Carter,et al.  Introducing a New Journal: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging , 2015, Biological Psychiatry.

[24]  A. Mitchell,et al.  Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta‐analysis , 2014, Acta psychiatrica Scandinavica.

[25]  Andrew J. Saykin,et al.  A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.

[26]  R. Sperling,et al.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.

[27]  W. M. van der Flier,et al.  Preclinical AD predicts decline in memory and executive functions in subjective complaints , 2013, Neurology.

[28]  Jin Fan,et al.  Functional Neural Correlates of Attentional Deficits in Amnestic Mild Cognitive Impairment , 2013, PloS one.

[29]  Meghan B. Mitchell,et al.  Confirmatory factor analysis of the ADNI neuropsychological battery , 2012, Brain Imaging and Behavior.

[30]  B. Hermann,et al.  Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease. , 2010, Neuropsychology.

[31]  J. Teresi,et al.  The Free and Cued Selective Reminding Test: evidence of psychometric adequacy , 2009 .

[32]  Andrea M Hussong,et al.  Integrative data analysis: the simultaneous analysis of multiple data sets. , 2009, Psychological methods.

[33]  Z. Khachaturian.  Alzheimer's & Dementia: The Journal of the Alzheimer's Association , 2008, Alzheimer's & Dementia.

[34]  Lars Bäckman,et al.  Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. , 2005, Neuropsychology.

[35]  D. Delis,et al.  The myth of testing construct validity using factor analysis or correlations with normal or mixed clinical populations: Lessons from memory assessment , 2003, Journal of the International Neuropsychological Society.

[36]  A. Monsch,et al.  The cerad neuropsychological assessment battery (Cerad-NAB)—A minimal data set as a common tool for German-speaking Europe , 2000, Neurobiology of Aging.

[37]  Isabelle Rouleau,et al.  Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease , 1992, Brain and Cognition.

[38]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[39]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[40]  F. Jessen,et al.  Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment. , 2017, Journal of Alzheimer's disease : JAD.

[41]  J. Trojanowski,et al.  Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. , 2016, Journal of Alzheimer's disease : JAD.

[42]  J. Trojanowski,et al.  Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. , 2015, Journal of Alzheimer's disease : JAD.

[43]  L. Kux.  OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .

[44]  W. Sturm,et al.  Neuropsychological assessment , 2007, Journal of Neurology.

[45]  R. Petersen,et al.  Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope , 1997, Alzheimer disease and associated disorders.

[46]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.